News
News Center
The Tianjin Municipal People's Government General Office has issued a document supporting the exploration and implementation of a tiered and categorized system for cell and gene therapies.
2025-02-18
On February 6, the General Office of the Tianjin Municipal People's Government issued the "Several Measures to Support Biopharmaceutical Innovation Across the Entire Industrial Chain in Tianjin," which mentions several key points throughout. Cell and Gene Therapy 。
(II) Strengthen basic research and tackle core technology challenges. Accelerate the development of specialized fields such as synthetic biology, modern Chinese medicine, radiopharmaceuticals, nucleic acid drugs, cell and gene therapies, "AI+Medicine," high-value medical consumables, brain science, and regenerative medicine. Strategically coordinate various science and technology programs, continuously advancing "project clusters" and "R&D pipelines," while strengthening cutting-edge exploration into novel targets and innovative mechanisms. Additionally, expedite research on new tools, methods, and standards for pharmaceutical and medical device R&D and evaluation. Explore the establishment of a diversified investment program under the Natural Science Fund in the biopharmaceutical sector, actively attracting social capital to support forward-looking and innovative applied basic research. Priority will be given to areas such as cutting-edge clinical diagnostic and treatment technologies, drug mechanisms of action, and efficacy evaluation. (The Municipal Science and Technology Bureau, Municipal Development and Reform Commission, and Municipal Industry and Information Technology Bureau will be responsible according to their respective duties.)
(Fourteen) Strengthen the new biopharmaceutical track. Enhance the development of nuclear medicine departments and ramp up graduate-level training in nuclear pharmacy. Encourage qualified Grade III hospitals to pursue accreditation for a "Radioactive Pharmaceutical Use License (Class IV)." Support research and development of nucleic acid drugs and delivery systems, accelerate the attraction of high-quality upstream and downstream enterprises, foster industry clustering, and establish specialized industrial parks. Support the Tianjin Free Trade Zone in innovating cell and gene therapy management models, strive for national pilot policies, and explore the implementation of a tiered and categorized system for cell and gene therapies. Supporting the research and development of next-generation, common brain-computer interface technologies, and driving the innovation and industrialization of core components, high-end instruments, and medical devices. (The Municipal Development and Reform Commission, Municipal Bureau of Industry and Information Technology, Municipal Investment Promotion Bureau, Municipal Health Commission, Municipal Drug Administration, Municipal Science and Technology Bureau, Municipal Education Commission, and relevant district people's governments will be responsible according to their respective duties.)
Reprint Notice: This article is reprinted from the official website of the Tianjin Municipal People's Government. If there is any infringement, please contact us for removal.
Related News
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy